Generated by AI
Theriva Biologics Inc. is a clinical-stage biotechnology company focused on developing therapeutics for cancer and related diseases with significant unmet medical needs. The company’s current pipeline centers on oncolytic adenovirus technology, including VCN-01, an investigational program designed to selectively attack tumor cells and support the delivery of co-administered cancer therapies. Theriva Biologics is also advancing microbiome-related candidates such as SYN-004 and SYN-020, which are intended to help preserve the gut microbiome during antibiotic treatment and address complications linked to microbiome disruption. Its programs span oncology, infectious disease prevention, and gastrointestinal health, reflecting a diversified approach to therapeutic development. Based in Rockville, Maryland, Theriva Biologics operates as a research-driven developer of novel treatment platforms for areas where current options remain limited.
Website9605 Medical Center Drive
Rockville, MD, 20850
United States
The latest articles about TOVX.
- Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer - - Data are consistent with an immune mediated mechanism of action for VCN-01 that may enhance the antitumor effects of a range of coadministered pancreatic cancer therapies - - The feasibility of administering more frequent repeated VCN-01 doses to potentially improve clinical outcomes in metastatic pancreat
Summary of Nov 2's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Summary of Jun 11's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Investors talking about TOVX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.